- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.06. | Upstream Bio präsentiert positive Phase-2-Studiendaten für Verekitug | 2 | Investing.com Deutsch | ||
| 14.06. | Upstream Bio presents positive Phase 2 trial data for verekitug | 2 | Investing.com | ||
| 14.06. | Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 | 2 | GlobeNewswire (USA) | ||
| 12.06. | JPMorgan stuft Upstream Bio wegen Umsetzungsrisiken herab | 5 | Investing.com Deutsch | ||
| 12.06. | JPMorgan downgrades Upstream Bio stock rating on execution risks | 1 | Investing.com | ||
| 10.06. | Upstream Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | Upstream Bio to Showcase Additional Efficacy Data from the Phase 2 VIBRANT Trial of Verekitug in CRSwNP in Oral Session at EAACI 2026 | 213 | GlobeNewswire (Europe) | WALTHAM, Mass., June 08, 2026 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory... ► Artikel lesen | |
| UPSTREAM BIO Aktie jetzt für 0€ handeln | |||||
| 03.06. | H.C. Wainwright startet Coverage für Upstream Bio mit "Buy" und hohem Kursziel | 4 | Investing.com Deutsch | ||
| 03.06. | H.C. Wainwright initiates Upstream Bio stock coverage with buy rating | 1 | Investing.com | ||
| 14.05. | Mizuho lowers Upstream Bio stock price target on operating spend tweaks | 1 | Investing.com | ||
| 14.05. | Mizuho senkt Kursziel für Upstream Bio wegen angepasster Betriebsausgaben | 1 | Investing.com Deutsch | ||
| 13.05. | Upstream Bio, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | Upstream Bio, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.04. | Upstream Bio stellt neue Daten zu Verekitug auf Fachkonferenz vor | 2 | Investing.com Deutsch | ||
| 17.04. | Upstream Bio to present verekitug data at medical conference | 1 | Investing.com | ||
| 02.04. | Truist senkt Kursziel für Upstream Bio wegen verzögertem Studienzeitplan | 4 | Investing.com Deutsch | ||
| 02.04. | Truist cuts Upstream Bio stock price target on trial timeline | 2 | Investing.com | ||
| 27.03. | Evercore ISI stuft Upstream Bio wegen fehlender kurzfristiger Katalysatoren herab | 1 | Investing.com Deutsch | ||
| 27.03. | Evercore ISI cuts Upstream Bio stock rating on lack of near-term catalysts | 1 | Investing.com | ||
| 26.03. | Upstream Bio, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 3 | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VALNEVA | 2,291 | +0,04 % | Valneva streicht Jobs - warum die Aktie dennoch steigt | ||
| VIVOSIM LABS | 0,468 | 0,00 % | VivoSim Labs, Inc.: VivoSim Provides Financial and Listing Compliance Update | SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim"), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,235 | +0,41 % | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update | Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
Strategic partnering remains a key priority, with multiple strategic discussions progressing, including... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 14,720 | +1,38 % | Sarepta's Q2 Earnings & Sales Beat Estimates, '26 Outlook Updated | ||
| TRAWS PHARMA | 0,543 | +2,05 % | Traws Pharma, Inc.: Traws Pharma Provides Updated Guidance on Influenza Prophylaxis Program | NEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, Traws, the Company), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral... ► Artikel lesen | |
| VERASTEM | 5,600 | -4,01 % | Verastem outlines October VS-7375 response-rate update while targeting LGSOC self-sustainability by end of 2026 | ||
| UNIQURE | 39,900 | -0,62 % | uniQure Inc.: uniQure Announces Second Quarter 2026 Financial Results and Provides Company Update | ~ U.S. and U.K. regulatory submissions for AMT-130 for Huntington's disease on track as planned for the third quarter of 2026 ~
~ Topline four-year data from the Phase I/II study of AMT-130 expected... ► Artikel lesen | |
| ZAI LAB LTD ADR | 20,600 | +1,98 % | Citi Raises Zai Lab Limited TP to USD45, Expects China Business to Stabilize in 2H26 | ||
| TRINITY BIOTECH | 12,500 | +0,56 % | Trinity Biotech plc: Trinity Biotech Partners with Latch Medical to Advance Biosensor-Guided Precision Drug Delivery Solutions Using CGM+ Technology | - Strategic collaboration and equity investment will combine Trinity Biotech's AI-native CGM+ wearable biosensor platform with Latch Medical's innovative intradermal drug delivery technology to develop... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 2,830 | -0,14 % | Voyager Therapeutics, Inc. - 8-K, Current Report | ||
| TVARDI THERAPEUTICS | 1,660 | +1,22 % | Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update | Topline results from healthy volunteer study and clinical development strategy for next-generation STAT3 inhibitor, TTI-109, anticipated in June Topline data from Phase 2 trial of TTI-101 in hepatocellular... ► Artikel lesen | |
| XBIOTECH | 1,960 | 0,00 % | XBiotech Inc.: XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis | IND Application for V-SPINE Study Completes 30-Day FDA Review Without Clinical Hold, Clearing Path for U.S. Patient Enrollment
AUSTIN, Texas, June 15, 2026 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:... ► Artikel lesen | |
| VANDA PHARMACEUTICALS | 4,324 | 0,00 % | Vanda Pharmaceuticals Inc.: Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results | Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%
Full-year 2026 total revenue guidance of $240-$290 million... ► Artikel lesen | |
| ZEVRA THERAPEUTICS | 9,800 | -1,80 % | Zevra outlines CHMP reexamination timing with Q4 opinion expected, as MIPLYFFA Orange Book listing extends to 2041 | ||
| TENAX THERAPEUTICS | 12,000 | +2,56 % | Tenax Therapeutics, Inc.: Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) ("Tenax" or "Tenax... ► Artikel lesen |
UPSTREAM BIO INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +0,07 % bei einem Aktienkurs von 7,255 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu UPSTREAM BIO INC finden Sie auf Wallstreet Online.